Validation of In Vitro and In Vivo Methods for Assessing Endocrine Disrupting Chemicals

Toxicologic Pathology

Volumn 28, Issue 3, 2000, Pages 432-437

  Ashby, John ^a  

^a NONE

Author keywords

assays; Endocrine disruptors; endocrine modulators; testing strategy; validation

Indexed keywords

XENOBIOTIC AGENT;

ANALYTIC METHOD; ASSAY; CHEMICAL ANALYSIS; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VALIDATION PROCESS;

ANIMALS; ENDOCRINE SYSTEM; FEMALE; HORMONE ANTAGONISTS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 0034125043     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262330002800312     Document Type: Article

References (36)

1. Ankley G., et al (30 authors) (1998). Overview of a workshop on screening methods for detecting potential (anti-)estrogenic/androgenic chemicals in wildlife. Environ Toxicol Chem 17: 68-87.
2. Anonymous (1997). Endocrine/Estrogen Letter, July 22. Washington, DC.
3. Ashby J. (1997). A hierarchical approach to the evaluation of chemicals for estrogenic and other endocrine-disrupting properties. Environ Toxicol Pharmacol 3: 87-90.
4. Ashby J., Elliott BM (1997). Reproducibility of endocrine disruption data. Regul Toxicol Pharmacol 26: 94-95 (editorial).
5. Ashby J., Houthoff E., Kennedy SJ, Stevens J., Bars R., Jekat FW, Campbell P., Van Miller J, Carpanini FM, Randall Glp (1997). The challenge posed by endocrine-disrupting chemicals. Environ Health Perspect 105: 164-169.
6. Ashby J., Tinwell H. (1998). Uterotrophic activity of bisphenol A in the immature rat. Environ Health Perspect 106: 719-720.
7. Ashby J., Tinwell H., Lefevre PA, Odum J., Paton D., Millward SW, Tittensor S., Brooks AN (1997). Normal sexual development of rats exposed to butyl benzyl phthalate from conception to weaning. Regul Toxicol Pharmacol 26: 102-118.
8. Ashby J., Waters MD, Preston A., Adler ID, Douglas GR, Fielder R., Shelby MD, Anderson D., Sofuni T., Gopalan Hnb, Becking G., Sonich-Mullin C. (1996). IPCS harmonization of methods for the prediction and quantification of human carcinogenic/mutagenic hazard, and for indicating the probable mechanism of action of carcinogens. Mutat Res 352: 153-157.
9. Ball M., Karcher W. (1995). The validation of alternative test methods. ATLA 23: 884-886.
10. Black LJ, Sato M., Rowley ER, Magee DE, Bekele A., Williams DC, Cullinan GJ, Bendele R., Kaufman FG, Bensch WR, Frolic CA, Termine JD, Bryant HU (1994). Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63-69.
11. Brzozowski AM, Pike Acw, Dauter Z., Hubbard RE, Bonn T., Engstrom O., Ohman L., Greene GL, Gustaffson J-A., Carlquist M. (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-757.
12. Campbell PM, Hutchinson TH (1998). Wildlife and endocrine disrupters: Requirement for hazard identification. Environ Toxicol Chem 17: 127-135.
13. Colborn T, Clement C, eds. (1992). Chemically-induced alterations in sexual and functional development: The wildlife-human connection. Princeton Scientific Publishing, Princeton, New Jersey.
14. Connor K., Ramamoorthy K., Moore M., Mustain M., Chen I., Safe S., Zacharewski T., Gillesby B., Joyeux A., Balaguer P. (1997). Hydroxylated polychlorinated biphenyls (PCB) as estrogens and antiestrogens: Structure activity relationships. Toxicol Appl Pharmacol 145: 111-113.
15. Cooke PS, Zhao Y., Hansen LG (1996). Neonatal polychlorinated biphenyl treatment increases adult testis size and sperm production in the rat. Toxicol Appl Pharmacol 136: 112-117.
16. Evans GL, Bryant HU, Magee DE, Turner RT (1996). Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137: 4139-4144.
17. Hess RA, Cooke PS (1996). Symposium overview—Endocrine modulation of reproduction. Fundam Appl Toxicol 29: 1-17.
18. Hill AB (1965). Environment and disease—Association or causation. Proc R Soc Med 58: 295-300.
19. Horwitz KB (1995). When tamoxifen turns bad. Endocrinology 136: 821-823 (editorial).
20. Jansen HT, Cooke PS, Porcelii J., Liu T-C., Hansen LG (1993). Estrogenic and antiestrogenic actions of PCBs in the female rat: In vitro and in vivo studies. Reprod Toxicol 7: 237-248.
21. Kelce WR, Lambright CR. Gray EL, Roberts KP (1997). Vinclozolin and p, p'DDE alter androgen-dependent gene expression: In vivo and in vitro confirmation of an androgen receptor-mediated mechanism. Toxicol Appl Pharmacol 142: 192-200.
22. Kelce WR, Stone CR, Laws SC, Gray EL, Kemppainen JA, Wilson EM (1995). Persistent DDT metabolite p, p'DDE is a potent androgen receptor antagonist. Nature 375: 581-585.
23. Ketzenellenbogen BS, Korach KS (1997). A new actor in the estrogen receptor drama. Endocrinology 138: 861-862 (editorial).
24. Kuiper Ggjm, Carlsson B., Grandien K., Enmark E., Haggblad J. Nilsson S., Gustafsson JA (1997). Comparison of the ligand binding specificity and transcript tissue distribution of oestrogen receptors alpha and beta. Endocrinology 138: 863-870.
25. McLachlan JA (1993). Functional toxicology: A new approach to detect biologically active xenobiotics. Environ Health Perspect 101: 386-387.
26. Nagel SC, Vom Saal FS, Thayer KA, Dhar MG, Boechler M., Welshons WV (1997). Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol. Environ Health Perspect 105: 70-76.
27. Reel JR, Lamb JC, Neal BH (1996). Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundam Appl Toxicol 34: 288-305.
28. Scialli AR (1997). Identifying teratogens: The tyranny of lists. Reprod Toxicol 11: 555-559.
29. Sharpe RM, Fisher JS, Millar MM, Jobling S., Sumpter JP (1995). Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. Environ Health Perspect 103: 1136-1143.
30. Shelby MD, Newbod RR, Tully DB, Chae K., Davis L. (1996). Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. Environ Health Perspect 104: 1296-1300.
31. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL (1997). Ovary- intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 18: 1595-1601.
32. Singletary K., MacDonald C., Wallig M. (1997). The plasticizer benzyl butyl phthalate (BBP) inhibits 7,12-dimethylbenz[a]anthracene (DMBA)—Induced rat mammary DNA adduct formation and tumorigenesis. Carcinogenesis 18: 1669-1673.
33. Sohoni P., Sumpter JP (1998). Several environmental oestrogens are also anti-androgens. J Endocrinol 158: 327-339.
34. Steinmetz R., Brown NG, Allen DL, Bigsby RM, Ben-Jonathan N. (1997). The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinology 138: 1780-1786.
35. Willson TM, Noris JD, Wagner BL, Asplin I., Baer P., Brown RH, Jones SA, Henke B., Sauls H., Wolfe S., Morris DC, McDonnell DP (1997). Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138: 3901-3911.
36. Yang NN, Venugopalan M., Hardikar S., Glasebrook A. (1996). Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 273: 1222-1225.